{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:17:04Z","timestamp":1788243424825,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The development of effective cancer immunotherapies is hindered by the lack of preclinical models that faithfully preserve tumor-immune interactions. Current approaches provide limited representation of immune components, creating a critical translational gap between laboratory findings and clinical outcomes. Precision Cut Tumor Slices (PCTS) offer a promising solution by maintaining complete tumor architecture including native immune cell populations and spatial organization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We established a PCTS platform using fresh bladder cancer specimens and optimized culture conditions to preserve tissue integrity and cell viability. Comprehensive phenotyping was performed using flow cytometry to characterize tumor and immune cell populations. Immune functionality was validated through CD3\/CD28 stimulation experiments measuring activation markers (CD69, CD137, HLA-DR) and cytokine secretion. Nine patient samples were treated with the PD-1 checkpoint inhibitor nivolumab to assess ex vivo effects. Additionally, multiplex immunofluorescence microscopy was employed on fixed PCTS as a readout for spatial distribution and cytotoxic effects of chemotherapy agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PCTS maintained viability of both cancer cells and diverse immune populations for up to six days. Functional validation demonstrated immune responsiveness upon T cell stimulation, with elevated activation markers and significantly increased secretion of inflammatory mediators including IFN\u03b3 and CXCL10, in treated as compared to control samples. The platform successfully addressed intra-tumor heterogeneity while maintaining experimental reproducibility across patient samples. Treatment with nivolumab revealed heterogeneous responses, with two out of nine samples (22%) demonstrating dose-dependent immune activation in the PCTS model, consistent with published response rates. Multiplex immunofluorescence analysis confirmed the ability to capture both immune-mediated responses and direct cytotoxic effects on cancer cells, enabling comprehensive evaluation of combination therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This validated PCTS platform represents a versatile human-derived tool for evaluating cancer immunotherapies while maintaining physiological tumor microenvironment complexity. The technical foundation established here enables future prospective studies correlating ex vivo responses with patient clinical outcomes, potentially advancing personalized treatment selection and reducing reliance on animal models in immunotherapy development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-05173-4","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:35:13Z","timestamp":1787970913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bladder cancer precision-cut tumor slices (PCTS) preserve functional immune microenvironment enabling ex vivo drug evaluation"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-8297","authenticated-orcid":false,"given":"Sarah","family":"Richtmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3924-8101","authenticated-orcid":false,"given":"Maja","family":"Radak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0644-6639","authenticated-orcid":false,"given":"Viktor","family":"Sincic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5339-7319","authenticated-orcid":false,"given":"Jenny","family":"Hugoson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0633-6130","authenticated-orcid":false,"given":"Valeriia","family":"Skoryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3794-1309","authenticated-orcid":false,"given":"Darcy","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-0370","authenticated-orcid":false,"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1421-8081","authenticated-orcid":false,"given":"Kristina","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"issue":"5","key":"5173_CR1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.eururo.2024.05.026","volume":"86","author":"NM Merrill","year":"2024","unstructured":"Merrill NM, Kaffenberger SD, Bao L, Vandecan N, Goo L, Apfel A, et al. Integrative drug screening and multiomic characterization of patient-derived bladder cancer organoids reveal novel molecular correlates of gemcitabine response. Eur Urol. 2024;86(5):434\u201344.","journal-title":"Eur Urol"},{"key":"5173_CR2","doi-asserted-by":"publisher","first-page":"1237565","DOI":"10.3389\/fimmu.2023.1237565","volume":"14","author":"C Kayser","year":"2023","unstructured":"Kayser C, Brauer A, Susanne S, Wandmacher AM. The challenge of making the right choice: patient avatars in the era of cancer immunotherapies. Front Immunol. 2023;14:1237565.","journal-title":"Front Immunol"},{"issue":"4","key":"5173_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1158\/2326-6066.CIR-24-1046","volume":"13","author":"N Lonberg","year":"2025","unstructured":"Lonberg N. The Problem with syngeneic mouse tumor models. Cancer Immunol Res. 2025;13(4):456\u201362.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"5173_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/026119291404200306","volume":"42","author":"J Bailey","year":"2014","unstructured":"Bailey J, Thew M, Balls M. An analysis of the use of animal models in predicting human toxicology and drug safety. Altern Lab Anim. 2014;42(3):181\u201399.","journal-title":"Altern Lab Anim"},{"issue":"1","key":"5173_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96\u2013108.","journal-title":"Eur Urol"},{"issue":"2","key":"5173_CR6","first-page":"233","volume":"50","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ. The use of intravesical chemotherapy and possibilities for improving its efficacy. Eur Urol. 2006;50(2):233.","journal-title":"Eur Urol"},{"issue":"3","key":"5173_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","volume":"34","author":"AV Balar","year":"2023","unstructured":"Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023;34(3):289\u201399.","journal-title":"Ann Oncol"},{"issue":"1","key":"5173_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.24.00340","volume":"43","author":"MD Galsky","year":"2025","unstructured":"Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from checkmate 274. J Clin Oncol. 2025;43(1):15\u201321.","journal-title":"J Clin Oncol"},{"issue":"11","key":"5173_CR9","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483\u201392.","journal-title":"Lancet Oncol"},{"issue":"1","key":"5173_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","volume":"21","author":"R Nadal","year":"2024","unstructured":"Nadal R, Valderrama BP, Bellmunt J. Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat Rev Clin Oncol. 2024;21(1):8\u201327.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"5173_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875\u201388.","journal-title":"N Engl J Med"},{"issue":"12","key":"5173_CR12","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.ccell.2024.10.016","volume":"42","author":"H Hamidi","year":"2024","unstructured":"Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, Guan X, et al. Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade. Cancer Cell. 2024;42(12):2098\u2013112. e4.","journal-title":"Cancer Cell"},{"key":"5173_CR13","doi-asserted-by":"publisher","first-page":"1235884","DOI":"10.3389\/fimmu.2023.1235884","volume":"14","author":"J van Dorp","year":"2023","unstructured":"van Dorp J, van der Heijden MS. The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition. Front Immunol. 2023;14:1235884.","journal-title":"Front Immunol"},{"issue":"1","key":"5173_CR14","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","volume":"14","author":"AG Robertson","year":"2023","unstructured":"Robertson AG, Meghani K, Cooley LF, McLaughlin KA, Fall LA, Yu Y, et al. Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nat Commun. 2023;14(1):2126.","journal-title":"Nat Commun"},{"key":"5173_CR15","doi-asserted-by":"publisher","first-page":"986598","DOI":"10.3389\/fimmu.2023.986598","volume":"14","author":"R Benitez","year":"2023","unstructured":"Benitez R, Yu K, Sirota M, Malats N, Pineda S. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer. Front Immunol. 2023;14:986598.","journal-title":"Front Immunol"},{"key":"5173_CR16","doi-asserted-by":"publisher","first-page":"1105026","DOI":"10.3389\/fonc.2022.1105026","volume":"12","author":"Z Chen","year":"2022","unstructured":"Chen Z, Chen D, Song Z, Lv Y, Qi D. Mapping the tumor microenvironment in bladder cancer and exploring the prognostic genes by single-cell RNA sequencing. Front Oncol. 2022;12:1105026.","journal-title":"Front Oncol"},{"key":"5173_CR17","doi-asserted-by":"publisher","first-page":"1221484","DOI":"10.3389\/fmed.2023.1221484","volume":"10","author":"S Golan","year":"2023","unstructured":"Golan S, Bar V, Salpeter SJ, Neev G, Creiderman G, Kedar D, et al. A clinical evaluation of an ex vivo organ culture system to predict patient response to cancer therapy. Front Med (Lausanne). 2023;10:1221484.","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"5173_CR18","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","volume":"27","author":"P Voabil","year":"2021","unstructured":"Voabil P, de Bruijn M, Roelofsen LM, Hendriks SH, Brokamp S, van den Braber M, et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat Med. 2021;27(7):1250\u201361.","journal-title":"Nat Med"},{"issue":"1\u20136","key":"5173_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/21681805.2022.2159519","volume":"57","author":"F Liedberg","year":"2023","unstructured":"Liedberg F, Abrahamsson J, Bernardo C, Blackberg M, Edsjo A, Heidenblad M, et al. UROSCAN and UROSCANSEQ: a large-scale multicenter effort towards translation of molecular bladder cancer subtypes into clinical practice - from biobank to RNA-sequencing in real time. Scand J Urol. 2023;57(1\u20136):2\u20139.","journal-title":"Scand J Urol"},{"key":"5173_CR20","doi-asserted-by":"crossref","unstructured":"Goldsborough T, O\u2019Callaghan A, Inglis F, Leplat L, Filby A, Bilen H et al. A novel channel invariant architecture for the segmentation of cells and nuclei in multiplexed images using InstanSeg. bioRxiv. 2024:2024.09.04.611150.","DOI":"10.1101\/2024.09.04.611150"},{"issue":"6021","key":"5173_CR21","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/315672a0","volume":"315","author":"AD Luster","year":"1985","unstructured":"Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature. 1985;315(6021):672\u20136.","journal-title":"Nature"},{"issue":"2","key":"5173_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/icb.2010.158","volume":"89","author":"JR Groom","year":"2011","unstructured":"Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89(2):207\u201315.","journal-title":"Immunol Cell Biol"},{"issue":"21","key":"5173_CR23","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"5173_CR24","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12(7):3049\u201362.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"5173_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"key":"5173_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fonc.2018.00400","volume":"8","author":"AF van de Merbel","year":"2018","unstructured":"van de Merbel AF, van der Horst G, van der Mark MH, van Uhm JIM, van Gennep EJ, Kloen P, et al. An ex vivo tissue culture model for the assessment of individualized drug responses in prostate and bladder cancer. Front Oncol. 2018;8:400.","journal-title":"Front Oncol"},{"issue":"7","key":"5173_CR27","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/cam4.720","volume":"5","author":"J Koerfer","year":"2016","unstructured":"Koerfer J, Kallendrusch S, Merz F, Wittekind C, Kubick C, Kassahun WT, et al. Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Med. 2016;5(7):1444\u201353.","journal-title":"Cancer Med"},{"issue":"6","key":"5173_CR28","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s00204-022-03295-1","volume":"96","author":"C Biel","year":"2022","unstructured":"Biel C, Martinec O, Sibering B, van Summeren K, Wessels AMA, Touw DJ, et al. Extending the viability of human precision-cut intestinal slice model for drug metabolism studies. Arch Toxicol. 2022;96(6):1815\u201327.","journal-title":"Arch Toxicol"},{"issue":"2","key":"5173_CR29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.euo.2022.01.008","volume":"5","author":"A Taber","year":"2022","unstructured":"Taber A, Prip F, Lamy P, Agerbaek M, Jensen JB, Steiniche T, et al. Immune contexture and differentiation features predict outcome in bladder cancer. Eur Urol Oncol. 2022;5(2):203\u201313.","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"5173_CR30","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/cells13110926","volume":"13","author":"V Sincic","year":"2024","unstructured":"Sincic V, Arlenhold KF, Richtmann S, Lilljebjorn H, Eriksson P, Sjodahl G, et al. Distinct infiltration of t cell populations in bladder cancer molecular subtypes. Cells. 2024;13(11):926.","journal-title":"Cells"},{"issue":"1","key":"5173_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nm.3984","volume":"22","author":"N Andor","year":"2016","unstructured":"Andor N, Graham TA, Jansen M, Xia LC, Aktipis CA, Petritsch C, et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med. 2016;22(1):105\u201313.","journal-title":"Nat Med"},{"issue":"10","key":"5173_CR32","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883\u201392.","journal-title":"N Engl J Med"},{"issue":"5","key":"5173_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/bjc.2016.172","volume":"115","author":"H Bronger","year":"2016","unstructured":"Bronger H, Singer J, Windmuller C, Reuning U, Zech D, Delbridge C, et al. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br J Cancer. 2016;115(5):553\u201363.","journal-title":"Br J Cancer"},{"issue":"3","key":"5173_CR34","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540\u2013e5625.","journal-title":"Cell"},{"issue":"10031","key":"5173_CR35","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet"},{"issue":"6","key":"5173_CR36","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024;35(6):485\u201390.","journal-title":"Ann Oncol"},{"issue":"19","key":"5173_CR37","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778\u201389.","journal-title":"N Engl J Med"},{"issue":"7","key":"5173_CR38","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell. 2017;171(7):1678\u201391. e13.","journal-title":"Cell"},{"issue":"44","key":"5173_CR39","doi-asserted-by":"publisher","first-page":"eadq6830","DOI":"10.1126\/sciadv.adq6830","volume":"10","author":"B Alsaed","year":"2024","unstructured":"Alsaed B, Smolander J, Laitinen H, Lin L, Bobik N, Lahtinen L, et al. Ex vivo modeling of precision immuno-oncology responses in lung cancer. Sci Adv. 2024;10(44):eadq6830.","journal-title":"Sci Adv"},{"key":"5173_CR40","doi-asserted-by":"publisher","first-page":"104662","DOI":"10.1016\/j.yrtph.2020.104662","volume":"114","author":"AM Avila","year":"2020","unstructured":"Avila AM, Bebenek I, Bonzo JA, Bourcier T, Davis Bruno KL, Carlson DB, et al. An FDA\/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs). Regul Toxicol Pharmacol. 2020;114:104662.","journal-title":"Regul Toxicol Pharmacol"},{"key":"5173_CR41","doi-asserted-by":"publisher","first-page":"105345","DOI":"10.1016\/j.yrtph.2023.105345","volume":"139","author":"AM Avila","year":"2023","unstructured":"Avila AM, Bebenek I, Mendrick DL, Peretz J, Yao J, Brown PC. Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA\/CDER perspective on considerations for development of new approach methodologies. Regul Toxicol Pharmacol. 2023;139:105345.","journal-title":"Regul Toxicol Pharmacol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05173-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05173-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05173-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:12:27Z","timestamp":1788243147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05173-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5173"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05173-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients approved participation by verbal and written consent, and the study was approved by the ethics committee at Lund University (2017\/269, Dnr 2020\u201305559 and Dnr 2022-03081-02). The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. All participants were informed about the purpose of the study, assured of confidentiality, and provided written consent prior to participation. Participation was voluntary, and respondents could withdraw at any time without consequence.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"468"}}